illumina stock: Nasdaq Overview & Investor Guide

Illumina (ILMN) — Stock

This article covers the publicly traded equity of Illumina, Inc. (ticker ILMN) listed on the Nasdaq exchange. If you are researching illumina stock, this guide explains what the company does, where the stock trades, important corporate events (including the GRAIL divestiture and GRAL listing), how to read its financials, analyst coverage, key risks, and practical resources for tracking quotes and filings. The goal is to help beginners and investors find verifiable, timely data and to point to trusted investor resources — with suggestions for using Bitget for market tracking and trading tools.

• Keyword focus: illumina stock appears throughout this guide for search clarity and navigation.
• What you will get: concise company overview, dated market snapshots, historical context (including the GRAIL spin-off), metrics investors commonly use, major risks, and where to find up-to-date quotes and filings.

Infobox / Quick facts (snapshot)

• Company: Illumina, Inc.
• Ticker: ILMN (Nasdaq)
• Primary listing currency: USD
• Sector / Industry: Healthcare / Life Sciences Instruments & Services (genomics, sequencing)
• Headquarters: San Diego, California, U.S. (company filings)
• Founded: 1998 (company history)
• IPO: Listed on Nasdaq (historical listing date in company filings)

As of January 24, 2026, according to Benzinga, illumina stock was quoted at $152.82 with a market capitalization reported at approximately $24.19 billion (source: Benzinga, Jan 24, 2026). For live and delayed quotes, consult major finance portals and company filings noted in the References section.

Company overview

Illumina develops and sells platforms for sequencing and array-based genomic analysis. The company's products include next-generation sequencing (NGS) instruments, consumables (reagents and flow cells), library preparation kits, and software for data analysis. Customers span research institutions, clinical laboratories, pharmaceutical companies, and applied markets like agriculture and forensics. Recurring revenue is largely driven by consumables and services tied to installed sequencing instruments.

For readers tracking illumina stock, understanding the revenue split between instruments (capital equipment) and consumables/services (recurring revenue) is important: consumables are the primary repeat-revenue driver for the business model and for forecasts cited by analysts.

Stock market listing and trading

Illumina trades on the Nasdaq under the ticker ILMN. Trading is in U.S. dollars during Nasdaq market hours. Quotes for illumina stock are available via major financial portals (e.g., Yahoo Finance, CNBC, MarketWatch) and in broker platforms. For investors who prefer an integrated trading and market-data experience, Bitget provides market monitoring tools, price alerts, and portfolio tracking that can include U.S. equity tickers for research convenience.

Note: The primary publicly traded instrument discussed here is Illumina common stock (ILMN). Derivatives and other instruments (options, swaps) exist in professional markets but are beyond this beginner-oriented guide.

Historical background and major corporate events

Illumina's history spans product innovation in DNA sequencing and several material corporate actions that have affected illumina stock over time. Key milestones include the company's founding in 1998, its growth through product launches and acquisitions, and significant corporate restructurings.

A recent and material corporate event for investors was the separation of GRAIL. The transaction changed the composition of Illumina’s assets and had direct implications for illumina stockholders.

GRAIL spin-off (GRAL)

• What happened: Illumina completed a divestiture related to GRAIL Inc., which resulted in a public listing under the ticker GRAL. The divestiture included a distribution of GRAL shares to existing Illumina shareholders as part of the transaction.
• Mechanics: The distribution and listing were completed per Illumina’s press releases and investor communications. Illumina’s corporate disclosures described the transfer of certain GRAIL assets and the distribution mechanics to ILMN shareholders. Illumina also retained a minority ownership stake in the newly listed GRAL entity per company statements (see Illumina press release for explicit retained-stake details and effective dates).
• Why it matters for illumina stock holders: The spin-off separated GRAIL’s business and financial results from Illumina’s core sequencing business, which can affect how investors value illumina stock (ILMN). Following the distribution, shareholders received direct exposure to GRAL while Illumina simplified its business focus on sequencing platforms and consumables.

(Reference: Illumina press release on GRAIL divestiture — see References section for reporting date and source.)

Business segments and revenue drivers

Illumina’s business is centered on sequencing systems, consumables, and associated software/services. For investors in illumina stock, the following product categories and revenue drivers are typically monitored:

• Sequencing instruments: Capital equipment sales that create installed base.
• Consumables: Reagents, flow cells, and kits required for each sequencing run — the largest recurring revenue contributor.
• Services and software: Data analysis tools, software subscriptions, assay-based services (e.g., certain clinical testing products).
• Clinical and applied markets: Growth depends on clinical adoption (diagnostics, oncology profiling, prenatal testing) and applied genomics (agriculture, microbiology).

Company filings (10-K and 10-Q) provide detailed revenue breakdowns by product and customer type; analysts use these to model recurring revenue and margin dynamics when valuing illumina stock.

Financial performance and metrics

Investors evaluating illumina stock commonly track these financial indicators:

• Revenue and revenue growth (quarterly and annual)
• Net income and diluted earnings per share (EPS)
• Gross margin and operating margin trends
• Free cash flow and cash conversion
• Balance sheet items: cash, short-term investments, and total debt
• Share count metrics: shares outstanding and diluted share count
• Valuation multiples: P/E (trailing and forward), price/sales (P/S), EV/Revenue

As of January 2026, analyst consensus cited in market summaries showed a forward P/E in the 29–32x range and expected earnings growth, which shaped premium valuations for illumina stock (source: Benzinga, Jan 24, 2026). For exact historical quarterly results and audited annuals, consult Illumina’s SEC filings (10-Q and 10-K).

Stock price performance and market data

Historical price performance for illumina stock includes multi-year appreciation tied to technology leadership in sequencing as well as volatility from regulatory, legal, and corporate events. Long-term performance figures illustrate how compounding returns have affected shareholder value:

• As of Jan 24, 2026, Benzinga reported that Illumina had produced an average annual return of 14.36% over the past 20 years, outperforming the market by about 5.59% annually over that period. Benzinga noted that a hypothetical $1,000 investment in ILMN twenty years earlier would be worth $14,961.29 based on the price cited at that time (source: Benzinga, Jan 24, 2026).

• Trading metrics often monitored by investors in illumina stock include 52-week high/low, average daily volume, beta (volatility vs. the market), and total shareholder return (TSR) relative to benchmarks like the S&P 500 and Nasdaq.

Technical indicators and momentum statistics (RSI, MACD, moving averages) are updated daily on financial portals and were summarized in market coverage as mixed in January 2026: illumina stock was trading modestly above its 12-month moving average while MACD readings suggested short-term bearish pressure — illustrating the importance of looking at multiple data points when interpreting price action (source: Benzinga, Jan 24, 2026).

Analyst coverage and investor sentiment

Illumina is covered by a wide set of sell-side analysts and independent research providers. Consensus analyst ratings, price targets, and revisions are commonly cited by investors evaluating illumina stock. A snapshot from January 2026 included the following themes (sourced to market summaries):

• Analyst consensus and targets: Benzinga reported a consensus price target near $130.24 with a Neutral average rating at the time, while some broker reports ranged from Hold to Buy. Several firms updated targets in early January 2026 (e.g., TD Cowen, Guggenheim, Canaccord Genuity — see Benzinga summary for dates and target levels).
• Growth versus valuation debate: Analysts cited expected earnings growth (e.g., EPS estimates and revenue forecasts around upcoming reporting dates) but also noted that Illumina traded at a premium multiple, implying markets priced in high future growth.

Investors tracking illumina stock should monitor rolling analyst updates and read underlying research notes for assumptions on instrument shipments, consumables growth, and the financial impact of corporate actions such as the GRAIL divestiture.

Major shareholders and insider ownership

Institutional investors typically hold a significant share of outstanding Illumina stock. Large mutual funds, ETFs, and investment managers appear in public holdings reports and 13F filings. Insider holdings (executives and directors) are disclosed in Form 4 and proxy filings; these items can show alignment or dilution trends (e.g., option grants, share-based compensation).

Following the GRAIL transaction, some institutional ownership patterns may have adjusted due to distribution mechanics and repositioning. For the most recent institutional holdings and insider transactions affecting illumina stock, consult public filings (SEC) and major market-data portals that aggregate 13F and beneficial ownership data.

Corporate actions affecting the stock

Key corporate actions that historically affect illumina stock price and shareholder value include:

• Spin-offs / divestitures: The GRAIL divestiture (creating GRAL) was a material action that changed Illumina’s asset base and cash/ownership dynamics.
• Share repurchases: Buyback programs affect shares outstanding and EPS; management commentary and proxy statements show planned repurchases and authorizations.
• Dividends: Historically, Illumina has prioritized reinvestment in R&D and buybacks over a regular dividend; check the latest investor communications for any changes.
• Financing: Companies may use debt or credit facilities to finance strategic transactions (e.g., financing related to divestitures); the capital structure changes are disclosed in press releases and filings and can influence enterprise value and risk perceptions.

All material corporate actions are documented in Illumina’s press releases and SEC filings; these should be consulted for dates, terms, and impacts on illumina stock.

Risks and controversies

Investors considering illumina stock should be aware of material risks described in company filings and reported by financial news outlets:

• Competitive threats: Other sequencing and genomics companies compete on price, throughput, and application-specific performance.
• Regulatory risk: Export controls, healthcare reimbursement policies, and regulatory approvals can materially affect clinical adoption and addressable markets (e.g., reimbursement decisions for clinical assays).
• Legal and IP disputes: Patent litigation or contractual disputes may affect operations or require settlements.
• Supply-chain and manufacturing risks: Delays or capacity constraints in reagents and consumables impact revenue recognition and customer satisfaction.
• Concentration of revenue: A meaningful portion of revenue comes from consumables and clinical customers; shifts in clinical reimbursement or customer concentration are risks to monitor.

A neutral, factual approach requires checking Illumina’s risk disclosures (10-K) for a comprehensive list and for updates tied to new developments that could affect illumina stock.

Recent developments (news)

• CMS reimbursement for TruSight Oncology Comprehensive: As of reporting in January 2026, Benzinga noted that Illumina secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive test at a rate of $2,989.55 per test, effective January 1. Market commentators expected this to support adoption in the U.S. healthcare system and to benefit clinical consumables revenue for Illumina (Benzinga, Jan 2026).

• Analyst actions and near-term earnings: Market summaries identified an upcoming earnings date (Feb 5, 2026) with consensus EPS and revenue estimates; analysts issued target changes in early January 2026 across several brokerages (Benzinga summary, Jan 24, 2026). These moves highlight the importance of monitoring quarterly earnings and guidance when following illumina stock.

• Price and momentum indicators: As of the market commentary in January 2026, illumina stock was trading modestly above its 12-month moving average, showing mixed momentum indicators (Benzinga, Jan 24, 2026).

(Reporting dates are included in the References section for each item.)

Valuation and investment considerations

Common valuation approaches applied to illumina stock include:

• Price-to-Earnings (P/E): Useful for comparing to peers and historical averages when the company forecasts positive earnings.
• Price-to-Sales (P/S) and EV/Revenue: Employed when comparing growth-stage companies or when earnings are variable.
• Discounted Cash Flow (DCF): A forward-looking approach focused on projected free cash flow and reinvestment needs.

Key factors investors examine for illumina stock:

• Growth outlook for sequencing adoption in research and clinical markets.
• Reimbursement trends for clinical assays (e.g., CMS decisions) and their effect on recurring consumables revenues.
• Competitive positioning and technological differentiation in throughput, accuracy, and cost-per-base.
• Profitability and margins, especially gross margins driven by consumables.
• Balance sheet strength and capital allocation policy (buybacks, dividends, acquisitions).

This guide remains neutral and factual: it does not give investment advice or specific buy/sell recommendations. Anyone considering positions in illumina stock should conduct their own due diligence and consult licensed financial advisors.

How to obtain stock information and investor resources

For reliable, up-to-date information about illumina stock, use these primary sources (names only — search directly on the providers’ platforms):

• Illumina Investor Relations (company press releases, earnings presentations, 10-K and 10-Q filings)
• U.S. Securities and Exchange Commission (EDGAR filings for official company reports)
• Major financial portals: Yahoo Finance, MarketWatch, Morningstar, CNBC
• Broker platforms and research aggregators for analyst ratings and price targets

For investors who want an integrated platform for tracking market data and managing positions, Bitget offers market monitoring tools, price alerts, portfolio tracking, and an intuitive interface to follow equity performance alongside other assets. Bitget Wallet is a recommended option when referencing Web3 wallets in related contexts.

See also

• GRAL (GRAIL Inc.) — the listed entity resulting from the GRAIL divestiture
• Thermo Fisher Scientific (peer in life sciences instruments)
• 10x Genomics, CRISPR Therapeutics, Guardant Health (companies in adjacent genomics/biotech fields)

References (selected sources and reporting dates)

• Benzinga market summary and analysis (Jan 24, 2026): market data snapshot, 20-year performance, market cap, price, analyst consensus and recent rating changes. (Reported: Jan 24, 2026.)
• Illumina press release on GRAIL divestiture (company investor relations): details on distribution mechanics and retained stake. (See Illumina investor communications; reporting dates in company materials.)
• Yahoo Finance (ILMN) — stock quotes and analyst aggregates (date-stamped quotes vary by provider; consult page for latest timestamp).
• Morningstar, CNBC, MarketWatch — market data and analyst coverage summaries.
• StockAnalysis (ILMN) — stock metrics and valuation indicators.

Note: Each item above is a named source; consult the provider’s current pages or the company’s SEC filings (EDGAR) for primary documents and exact timestamps.

External resources for live quotes and filings (names only)

• Illumina Investor Relations
• U.S. SEC EDGAR
• Yahoo Finance (ILMN)
• Morningstar (ILMN)
• MarketWatch (ILMN)
• CNBC Markets (ILMN)

Practical checklist for tracking illumina stock (step-by-step)

1. Monitor the latest Illumina 10-Q/10-K for revenue mix, margins, and explicit disclosures on corporate actions (e.g., GRAIL divestiture details).
2. Check consensus analyst estimates and recent revisions on finance portals before earnings announcements.
3. Watch reimbursement and regulatory news (CMS decisions, FDA approvals) that can affect clinical adoption and consumables revenue.
4. Track institutional 13F filings and insider Form 4 disclosures for material position changes.
5. Use Bitget or your preferred trading platform to set price alerts, follow watchlists, and aggregate news feeds for illumina stock.

Frequently asked questions (FAQ)

Q: What is the ticker symbol for illumina stock? A: The ticker is ILMN on the Nasdaq exchange.

Q: Is Illumina a clinical diagnostics company or a sequencing tools company? A: Illumina is primarily a sequencing and genomic analysis platform company that sells instruments, consumables, and software/services used in research and clinical applications.

Q: How did the GRAIL transaction affect illumina stockholders? A: Illumina’s divestiture of GRAIL resulted in the distribution of GRAL shares to Illumina shareholders and a retained minority stake by Illumina as described in company press releases and filings. The separation refocused Illumina on its core sequencing business and created direct shareholder exposure to GRAL.

Q: Where can I find official Illumina financial statements? A: Official financial statements are filed with the U.S. SEC (EDGAR) and released via Illumina’s Investor Relations materials.

More on using Bitget for market tracking

For users who want an integrated market and portfolio experience, Bitget provides tools to follow price action, set alerts, and consolidate watchlists. While Bitget is known in crypto markets, its research and portfolio tools can be used to monitor publicly listed equities such as illumina stock alongside other assets. Bitget Wallet is recommended when discussing Web3 custody for digital assets.

Further exploration: create a watchlist for ILMN on your chosen platform, add GRAL if you own distributed shares, and set alerts for earnings release dates and material regulatory items.

Final notes and next steps

This guide presents a neutral, factual overview of illumina stock, including company activities, the GRAIL divestiture, valuation considerations, risks, and where to find timely data. For actionable items, consider these next steps:

• Review Illumina’s latest 10-K and recent 10-Q for full financial detail and explicit disclosures on the GRAIL transaction (dates and retained stake terms).
• Track the next earnings release and management commentary to see guidance changes that may influence illumina stock price.
• Use Bitget or your preferred platform to set price alerts and consolidate news feeds on ILMN and GRAL.

Further exploration and monitoring will keep you informed as new data and corporate actions are reported.